Investor

Active Biotech is developing pharmaceutical products within medical areas where the immune defense is of significant importance like inflammatory disease and various forms of cancer.

Active Biotech’s share is listed on the NASDAQ OMX Nordic Exchange (Stockholm) since 1986 and the company has approximately 16,400 shareholders.

Short Name
ACTI

Financial Reports

Latest Presentation

Infocus interview with CEO Helen Tuvesson at Redeye Technology & Life Science Day 2024

Events and Financial Calendar

Date: February 13, 2025
Date: May 28, 2025

Helén Tuvesson

IR Contact

Phone: +46 46 19 21 56

E-mail: helen.tuvesson@activebiotech.com

Hans Kolam

IR Contact

Phone: +46 46 19 20 44

E-mail: hans.kolam@activebiotech.com